Haleon extends its India oral care push, shares backed by cautious analyst views

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 11:10.

Haleon (GB00BMX86B70) continues to allocate capital to growth markets, with a particular focus on India’s oral care segment. The London-listed consumer health group, part of the FTSE 100, combines this push with a medium-term outlook for high single-digit operating profit growth, according to recent guidance and analyst commentary.

India investment in oral care

On 8 June 2026, Haleon disclosed a significant investment program aimed at expanding its oral care capacity in India, with media reports citing an outlay of around 233.1 million dollars for new facilities and capabilities in the country’s fast-growing dental segment. This move is designed to strengthen brands such as Sensodyne in a market where rising incomes and awareness of preventive health drive demand for premium oral care products.

The India expansion adds to Haleon’s broader footprint in emerging markets and aligns with its strategy to focus on categories with durable consumer demand, such as oral health and vitamins. India’s healthcare and consumer sectors have been growing at mid- to high single-digit rates, which offers Haleon an opportunity to compound revenues and margins over time, particularly if the investment translates into higher local market share.

Analyst adjustments and consensus

Analyst coverage of Haleon remains active, with several research houses updating their views in recent weeks. Berenberg adjusted its forecasts following a weaker-than-expected first quarter but reiterated its Buy recommendation, reflecting a belief in Haleon’s long-term consumer health positioning despite near-term pressure on growth metrics. At the same time, Rothschild & Co Redburn downgraded the stock to Neutral, signaling more cautious expectations for upside after the initial post-spin-off re-rating.

MarketScreener data show a last closing price of about 3,483 pence for Haleon on the London Stock Exchange, with an average analyst price target around 4,136 pence, implying moderate upside potential based on current consensus. The stock trades on a price-to-earnings ratio near the high teens, which places it in line with other established consumer health names, and offers a dividend yield slightly above 2 percent based on the latest distribution of £0.049 per share.

The products behind the stock

Haleon generates most of its revenue from branded consumer health products in oral care, pain relief, respiratory health, digestive health and vitamins, minerals and supplements. One of its flagship global products is Sensodyne, a toothpaste formulated for sensitive teeth that has strong market positions in Europe, North America and Asia and benefits directly from the company’s investment in oral care capacity in markets such as India.

Where the Haleon shares trade today

The Haleon shares (GB00BMX86B70) most actively trade on the London Stock Exchange, with recent data showing a closing level around 348.20 pence and a market capitalization of roughly £30.7 billion as of 2026-06-26.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell securities. All data were obtained from sources considered reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.